Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D 0002109116 XXXXXXXX LIVE Common Stock, $0.0001 par value 03/31/2026 false 0001855485 320703408 Calidi Biotherapeutics, Inc. 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 Chellsea Noelle Cartoscelli 9165040529 2315 Capitol Avenue Sacramento CA 95816 0002109116 N Gavrilov Ognian Anguelov OO N X1 20000.00 0.00 20000.00 0.00 20000.00 N 0.3 IN Common Stock, $0.0001 par value Calidi Biotherapeutics, Inc. 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 Ognian Anguelov Gavrilov 2315 Capitol Avenue, Sacramento, CA 95816 Managing Partner, Gavrlilov & Brooks, 2315 Capitol Avenue, Sacramento, CA 95816 No. No. United States of America Not Applicable. This Schedule 13D relates to the disposition of securities by the Reporting Person. The Reporting Person has effected dispositions of Shares as described in Item 5, resulting in beneficial ownership of approximately 0.3% of the outstanding Shares. The Reporting Person does not currently have any plans or proposals that relate to or would result in any of the actions described in Item 4 of Schedule 13D. However, the Reporting Person may, from time to time, acquire or dispose of securities of the Issuer in the open market or otherwise, depending on market conditions and other factors. 20,000.00 0 20,000.00 0 March 31, 2026 Not Applicable Gavrilov Ognian Anguelov Ognian Anguelov Gavrilov Ognian Anguelov Gavrilov, Managing Partner 03/31/2026